Chemical composition of circulating native and desialylated low density lipoprotein: what is the difference?

Abstract

Atherosclerosis and related cardiovascular disorders remain the leading global cause of morbidity and mortality. Modified low density lipoprotein (LDL) is considered to play a crucial role in atherosclerosis development. During the past decades, several types of atherogenic LDL modification have been discovered. Desialylation was one of the atherogenic modifications observed in circulating atherogenic LDL in vivo. Sialic acid level negatively correlates with triglyceride and cholesterol contents. Desialylated LDL is small, dense and highly susceptible to oxidation, as reported for hyperlipidemic conditions. This atherogenic modification leads to increased cholesterol intake by macrophages and smooth-muscle cells, and is also associated with other pathologies, such as diabetes mellitus. Moreover, these conditions provoke damage and desialylated LDL particles may trigger autoimmune reactions in macrophages and B-cells.

Keywords

Desialylation / desialylated low density lipoprotein / modified low density lipoprotein / sialic acid / atherosclerosis

References

[1] Mozaffarian D,Go AS,Blaha MJ,de Ferranti S,Fullerton HJ,Huffman MD,Kissela BM,Lichtman JH,Liu S,Matchar DB,Mohler ER3rd,Muntner P,Nasir K,Nichol G,Pandey DK,Rodriguez CJ,Stein J,Turan TN,Willey JZ,Yeh RW.Heart disease and stroke statistics--2015 update: a report from the american heart association..Circulation2015;131:e29-322

[2] Aluganti Narasimhulu C,Selvarajan K,Sengupta B,Parthasarathy S.Atherosclerosis--do we know enough already to prevent it?.Curr Opin Pharmacol2016;27:92-102

[3] Parhofer KG.Increasing HDL-cholesterol and prevention of atherosclerosis: a critical perspective..Atheroscler Suppl2015;18:109-11

[4] Ridker PM.LDL cholesterol: controversies and future therapeutic directions..Lancet2014;384:607-17

[5] Ference BA,Alesh I,Mirowska KK,Kahn J,Williams Sr KA.Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis..J Am Coll Cardiol2012;60:2631-9

[6] Soran H,Durrington P.Evidence-based goals in LDL-C reduction..Clin Res Cardiol2017;106:237-48 PMCID:PMC5360845

[7] Rahman A,Islam AK,Sarker SA.A young male with familial hypercholesterolemia..J Saudi Heart Assoc2012;24:261-4 PMCID:PMC3809505

[8] Norata GD,Catapano AL.New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs..Eur Heart J2013;34:1783-9 PMCID:PMC3857929

[9] Thompson PD,Zaleski A.Statin-associated side effects..J Am Coll Cardiol2016;67:2395-410

[10] Diffenderfer MR.The composition and metabolism of large and small LDL..Curr Opin Lipidol2014;25:221-6

[11] Filipovic I,Mraz W,Buddecke E.Sialic-acid content of low-density lipoproteins controls their binding and uptake by cultured cells..Eur J Biochem1979;93:51-5

[12] Tertov VV,Sobenin IA,Orekhov AN.Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions..Exp Mol Pathol1995;62:166-72

[13] Harada LM,Passarelli M.Lipoprotein desialylation simultaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages..Atherosclerosis1998;139:65-75

[14] Orekhov AN,Sobenin IA,Chistiakov DA.Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease..Int J Mol Sci2014;15:12807-41 PMCID:PMC4139876

[15] Sánchez-Quesada JL,Ordó-ez-Llanos J.Electronegative low-density lipoprotein. A link between apolipoprotein B misfolding, lipoprotein aggregation and proteoglycan binding..Curr Opin Lipidol2012;23:479-86

[16] Ivanova EA,Orekhov AN.LDL electronegativity index: a potential novel index for predicting cardiovascular disease..Vasc Health Risk Manag2015;11:525-32 PMCID:PMC4559248

[17] Estruch M,Ordó-ez Llanos J.Electronegative LDL: a circulating modified LDL with a role in inflammation..Mediators Inflamm2013;2013:181324 PMCID:PMC3766570

[18] Chu CS,Lu LS,Yilmaz HR,Sawamura T,Lai WT,Lu J.Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor..PLoS One2013;8:e70533 PMCID:PMC3738565

[19] Estruch M,Beloki L,Ordó-ez-Llanos J.CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes..Atherosclerosis2013;229:356-62

[20] Sevanian A,Ziouzenkova O.Low density lipoprotein (LDL) modification: basic concepts and relationship to atherosclerosis..Blood Purif1999;17:66-78

[21] Lee AS,Chan HC,Chang CM,Lee YT,Chen CH.Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell-released chemokines..Apoptosis2012;17:1009-18

[22] Chen CY,Lee AS,Chow LP,Chen H,Chen CH.The most negatively charged low-density lipoprotein L5 induces stress pathways in vascular endothelial cells..J Vasc Res2012;49:329-41

[23] Mogilenko DA,Trulioff AS,Dizhe EB,Zhakhov AV,Perevozchikov AP.Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and Toll-like receptor 4 activation in human macrophages..J Biol Chem2012;287:5954-68 PMCID:PMC3285363

[24] Chan HC,Chu CS,Shen MY,Hsu JF,Chan HC,Lai WT,Sheu SH,Chen CH.Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation..Blood2013;122:3632-41 PMCID:PMC3837512

[25] Kannan Y,Aluganti Narasimhulu C,Wewers MD.Oxidatively modified low density lipoprotein (LDL) inhibits TLR2 and TLR4 cytokine responses in human monocytes but not in macrophages..J Biol Chem2012;287:23479-88 PMCID:PMC3390624

[26] Niccoli G,De Spirito M,Cosentino N,Conte M,Arcovito G.Impact of electronegative low-density lipoprotein on angiographic coronary atherosclerotic burden..Atherosclerosis2012;223:166-70

[27] Hirowatari Y,Yoshizawa J.Increase of electronegative-LDL-fraction ratio and IDL-cholesterol in chronic kidney disease patients with hemodialysis treatment..Lipids Health Dis2012;11:111 PMCID:PMC3539864

[28] Hsu JF,Lu J,Chen FY,Chen JL,Ballantyne CM,Chen CH.Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor..PLoS One2014;9:e107340 PMCID:PMC4159324

[29] Maranhão RC,Strunz CC.Lipoprotein (a): structure, pathophysiology and clinical implications..Arq Bras Cardiol2014;103:76-84

[30] Enkhmaa B,Zhang W,Li XD,Pollard RB,Berglund L.HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels..Arterioscler Thromb Vasc Biol2013;33:387-92 PMCID:PMC4537858

[31] Helgadottir A,Thorleifsson G,Patel RS,Jones GT,Eapen DJ,Tregouet DA,Emmerich J,Gottsäter A,Lindholt JS,Ferrell RE,Elmore JR,Grarup N,Witte DR,Pedersen O,Gaetani E,Wijmenga C,Ronkainen A,Blankensteijn JD,Wells PS,Soria JM,Peden JF,Mayosi BM,Strawbridge RJ,Gertow K,Nyyssönen K,Smit AJ,Giral P,de Faire U,Hamsten A,Olafsson I,Samani NJ,Markus HS,Dichgans M,Kuhlenbäumer G,Stoll M,Rothwell PM,Kuivaniemi H,Valdimarsson E,Gudbjartsson DF,Quyyumi AA,Farrall M,Stefansson K.Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism..J Am Coll Cardiol2012;60:722-9

[32] Riches K.Lipoprotein(a): cellular effects and molecular mechanisms..Cholesterol2012;2012:923289 PMCID:PMC3443569

[33] Kwon SW,Hong BK,Choi EY,Rhee JH,Ma DW,Mun HS,Park JK,Yoon YW,Kwon HM.Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients..Int J Cardiol2013;167:1990-4

[34] Kamstrup PR,Nordestgaard BG.Extreme lipoprotein(a) levels and improved cardiovascular risk prediction..J Am Coll Cardiol2013;61:1146-56

[35] Gurdasani D,Tsimikas S,Luben RN,Pomilla C,Khaw KT,Sandhu MS.Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study..Arterioscler Thromb Vasc Biol2012;32:3058-65 PMCID:PMC4210842

[36] Fernández-Higuero JA,Martín C,Arrondo JL.Human LDL structural diversity studied by IR spectroscopy..PLoS One2014;9:e92426 PMCID:PMC3958539

[37] Segrest JP,De Loof H.Structure of apolipoprotein B-100 in low density lipoproteins..J Lipid Res2001;42:1346-67

[38] Bartlett AL.All low density lipoprotein particles are partially desialylated in plasma..Atherosclerosis1998;138:237-45

[39] Tertov VV,Sobenin IA,Gotto AMJr.Carbohydrate composition of protein and lipid components in sialic acid-rich and -poor low density lipoproteins from subjects with and without coronary artery disease..J Lipid Res1993;34:365-75

[40] Swaminathan N.The monosaccharide composition and sequence of the carbohydrate moiety of human serum low density lipoproteins..Biochemistry1976;15:1516-22

[41] Orekhov AN,Mukhin DN.Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients..Biochem Biophys Res Commun1989;162:206-11

[42] Ruelland A,Legras B,Cloarec L.LDL sialic acid content in patients with coronary artery disease..Clin Chim Acta1993;221:127-33

[43] Lindbohm N. Sialic acid in lipoproteins: with a special reference to low density lipoproteins. Available from: https://helda.helsinki.fi/handle/10138/22467. [Last accessed on Sep 6, 2017]

[44] Barbosa DS,Araújo FB,Hirata MH.Sialic acid and oxidizability of low density lipoprotein subfractions of hyperlipidemic patients..Clin Biochem1995;28:435-41

[45] Millar JS,Shepherd J.Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions..Atherosclerosis1999;145:253-60

[46] Ivanova EA,Melnichenko AA,Orekhov AN.Small dense low-density lipoprotein as biomarker for atherosclerotic diseases..Oxid Med Cell Longev2017;2017:1273042 PMCID:PMC5441126

[47] Melajärvi N,Miettinen TA.Sialic acids and the metabolism of low density lipoprotein..J Lipid Res1996;37:1625-31

[48] Lindbohm N,Miettinen TE.Sialic acid content of LDL and lipoprotein metabolism in combined hyperlipidemia and primary moderate hypercholesterolemia..Clin Chim Acta1999;285:69-84

[49] Chappey B,Foos E,Guermonprez JL,Myara I.Sialic acid content of LDL in coronary artery disease: no evidence of desialylation in subjects with coronary stenosis and increased levels in subjects with extensive atherosclerosis and acute myocardial infarction: relation between desialylation and in vitro peroxidation..Arterioscler Thromb Vasc Biol1998;18:876-83

[50] Lindbohm N,Rajaratnam RA.Sialic acid content of low-density lipoprotein in women with coronary artery disease..J Lab Clin Med2000;136:110-5

[51] Orekhov AN,Bobryshev YV.Ruiz M.Chapter 2: Naturally occurring multiple-modified low density lipoprotein..Blood Lipids and Lipoproteins.2015;New YorkNova Science Publishers Inc13-54

[52] Twardowski L,Michaelsen J,Hofmann U,Müller S,Steuer K,Schwab M,Torzewski M.Enzymatically modified low-density lipoprotein is present in all stages of aortic valve sclerosis: implications for pathogenesis of the disease..J Am Heart Assoc2015;4:e002156 PMCID:PMC4845139

[53] Guo S,Yang N,Li F,Li F.Measurement of sialic acid from lipoproteins and human plasma by liquid chromatography-tandem mass spectrometry..Se Pu2014;32:1197-200

[54] Sobenin IA,Grechko AV.Small dense and desialylated low density lipoprotein in diabetic patients..Vessel Plus2017;1:29-37

[55] Zakiev ER,Melnichenko AA,Ivanova EA.Lipid composition of circulating multiple-modified low density lipoprotein..Lipids Health Dis2016;15:134 PMCID:PMC4995786

[56] Trpkovic A,Stanimirovic J,Mousa SA,Jevremovic D.Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases..Crit Rev Clin Lab Sci2015;52:70-85

[57] Gradinaru D,Ionescu C.Oxidized LDL and NO synthesis--biomarkers of endothelial dysfunction and ageing..Mech Ageing Dev2015;151:101-13

[58] Delporte C,Vanhamme L,Zouaoui Boudjeltia K.Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies..Mediators Inflamm2013;2013:971579 PMCID:PMC3742028

[59] Rios FJ,Pecenin M,Wang Y,Jancar S.Uptake of oxLDL and IL-10 production by macrophages requires PAFR and CD36 recruitment into the same lipid rafts..PLoS One2013;8:e76893 PMCID:PMC3793910

[60] Yang K,Liu Z,Mao J,Wang Y,Zeng Y,Chen Q,Shen W.Oxidized low-density lipoprotein promotes macrophage lipid accumulation via the toll-like receptor 4-Src pathway..Circ J2015;79:2509-16

[61] Zeya B,Chandra NC.Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1): a chameleon receptor for oxidized LDL..Biochemistry2016;55:4437-44

[62] Parthasarathy S,Garelnabi MO.Oxidized low-density lipoprotein..Methods Mol Biol2010;610:403-17 PMCID:PMC3315351

[63] Oliveira CL,Monteiro AM.Effect of oxidation on the structure of human low- and high-density lipoproteins..Biophys J2014;106:2595-605 PMCID:PMC4070168

[64] Estruch M,Beloki L,Benitez S.The induction of cytokine release in monocytes by electronegative low-density lipoprotein (LDL) is related to its higher ceramide content than native LDL..Int J Mol Sci2013;14:2601-16 PMCID:PMC3588005

[65] Ke LY,Bair H.The underlying chemistry of electronegative LDL's atherogenicity..Curr Atheroscler Rep2014;16:428

[66] Sánchez-Quesada JL.Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus..Endocrinol Nutr2013;60:518-28

[67] Younis NN,Pemberton P,Elseweidy MM.Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes..Clin Sci (Lond)2013;124:343-9

[68] Del Turco S.An update on advanced glycation endproducts and atherosclerosis..Biofactors2012;38:266-74

[69] Grewal T,Burgess JW,Stanley KK.Desialylated LDL uptake in human and mouse macrophages can be mediated by a lectin receptor..Atherosclerosis1996;121:151-63

[70] Bhakdi S,Kirchmann R,Weise E,Walev I.On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety..J Exp Med1995;182:1959-71

[71] Klouche M,Gerl V,Husmann M,Messner M.Atherogenic properties of enzymatically degraded LDL: selective induction of MCP-1 and cytotoxic effects on human macrophages..Arterioscler Thromb Vasc Biol1998;18:1376-85

[72] Klouche M,Hemmes M,Kanse SM,Bhakdi S.Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers..Arterioscler Thromb Vasc Biol1999;19:784-93

[73] Tertov VV,Gabbasov ZA,Jaakkola O,Nikkari T,Orekhov AN.Multiple-modified desialylated low density lipoproteins that cause intracellular lipid accumulation. Isolation, fractionation and characterization..Lab Invest1992;67:665-75

[74] Dousset N,Taus M,Curatola G,Valdiguié P.Effect of desialylation on low density lipoproteins: comparative study before and after oxidative stress..Biochem Mol Biol Int1994;32:555-63

[75] Barbosa DS,Araújo FB,Hirata MH.Sialic acid and oxidizability of low density lipoprotein subfractions of hyperlipidemic patients..Clin Biochem1995;28:435-41

[76] Tertov VV,Kaplun VV.Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro..Free Radic Res1998;29:165-73

[77] Oztürk Z,Görgün FM,Bilgen D,Sözer V,Kökoğlu E.The relationship between lipid peroxidation and LDL desialylation in experimental atherosclerosis..Toxicol Mech Methods2007;17:265-73

[78] Tertov VV,Sobenin IA,Bovin NV.Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein..Atherosclerosis2001;159:103-15

[79] Mahajan VS.Sialic acids and autoimmune disease..Immunol Rev2016;269:145-61 PMCID:PMC4769436

[80] Macauley MS,Paulson JC.Siglec-mediated regulation of immune cell function in disease..Nat Rev Immunol2014;14:653-66 PMCID:PMC4191907

[81] Hutzler S,Naito-Matsui Y,Winkler TH,Nitschke L.The ligand-binding domain of Siglec-G is crucial for its selective inhibitory function on B1 cells..J Immunol2014;192:5406-14

[82] O'Neill AS,Mullen GE.Sialoadhesin - a macrophage-restricted marker of immunoregulation and inflammation..Immunology2013;138:198-207 PMCID:PMC3573273

[83] Sobenin IA,Zhelankin AV,Kaikkonen J,Orekhov AN.Low density lipoprotein-containing circulating immune complexes: role in atherosclerosis and diagnostic value..Biomed Res Int2014;2014:205697 PMCID:PMC4087281

[84] Burut DF,Ferns GA.The role of immune complexes in atherogenesis..Angiology2010;61:679-89

[85] Montano EN,Almazan F,Witztum JL.Development and application of a nonradioactive binding assay of oxidized low-density lipoprotein to macrophage scavenger receptors..J Lipid Res2013;54:3206-14 PMCID:PMC3793625

[86] Tertov VV,Orekhov AN,Solakivi T.Characteristics of low density lipoprotein isolated from circulating immune complexes..Atherosclerosis1996;122:191-9

[87] Schultze HE.Carbohydrate content of different blood components..Med Grundlogenforsch1960;3:357

[88] Ayrault-Jarrier M.Action des detergents sur une β-lipoproteine lumaine isoleé: etude de l'extractibilité des lipids..Bull Soc Chim Biol (Paris)1961;43:153-65(in French)

[89] Marshall WE.The carbohydrate constituents of human serum-lipoprotein: galactose, mannose, glucosamine, and sialic acid..Arch Biochem Biophys1962;98:271-3

[90] Kwiterovich P,Simon A.Isolation and partial characterization of the glycopeptides from human plasma low density lipoproteins..Circ Suppl III1974;49-50:267